Menu
Recruiting NCT07252687

The Effect of Gender-affirmative Measures on Breast Perception in Trans Men

Observational Transgender Gender Dysphoria in Adolescents and Adults

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: quality of life questionnaire- iTransQoL, chest dysphoria measure.
Who it may be relevant to
Registry conditions: Transgender, Gender Dysphoria in Adolescents and Adults. Basic parameters: from 16 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Austria
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Effect of Gender-affirmative Measures on Breast Perception in Trans Men (TRANSBREAST) - a Prospective Cohort Study

Overview

Breast dysphoria in transmasculine or genderdiverse individuals is a distinct psychological burden associated with depression, anxiety and suicidality. The aim is to systematically investigate the effect of GAHT (gender-affirming hormone therapy) and mastectomy on this form of dysphoria. The primary objective of this study is to analyse and investigate the psychological and physical effects of breast development on trans men or genderdiverse individuals. A secondary objective is to determine the extent to which the stress affects the well-being of trans men depending on the coping strategies used (binding vs. taping).

Interventions

  • Other quality of life questionnaire- iTransQoL, chest dysphoria measure
    Before starting treatment, participants should complete the Chest Dysphoria Measure and iTransQoL questionnaires (=time point 0). The second time point for completing the questionnaires again is 3 months after starting hormone therapy. Subsequently, the questionnaires should be completed a third time after breast-affirming surgery. The final survey takes place two years after time point 0, or 6 months after the previous survey.

Primary outcome measures

  • Chest Dysphoria Measure Score [Time frame: From enrollment to the end of observation after 2 years]

Eligibility criteria

Inclusion criteria

  • AFAB (Assigned Female At Birth)
  • before starting GAHT
  • before mastectomy

Exclusion criteria

  • Ongoing GAHT
  • Mastectomy already performed
  • Lack of capacity to give consent
  • Insufficient knowledge of German

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

Austria · 1 center
  • Medical University Innsbruck — Innsbruck

Identifiers

NCT: NCT07252687 · 1125/2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗